高级检索

    右美托咪定复合艾司氯胺酮对乳腺癌患者术后焦虑及神经精神症状的影响

    Effect of dexmedetomidine combined with esketamine on postoperative anxiety and neuropsychiatric symptoms in breast cancer patients

    • 摘要: 目的 探讨右美托咪定复合艾司氯胺酮对乳腺癌根治术后患者焦虑及神经精神症状的影响。方法 选择拟在静脉复合全身麻醉下行择期乳腺癌根治术患者130例,采用随机数字表法将所有患者分为对照组(C组)、艾司氯胺酮组(ES组)、艾司氯胺酮复合右美托咪定组(ES+DE组)。C组、ES组及ES+DE组基础用麻醉药物一致,各组持续输注相应实验用麻醉药物,术后ES组及ES+DE组加入相应的药物进行镇痛。对比各组术中心率(HR)、平均动脉压(MAP)变化,记录术后不良反应、神经精神症状发生情况,最后评估各组镇痛及焦虑评分情况。结果 3组乳腺癌患者一般资料差异无统计学意义;在拔管(T2)时,与C组及ES组比较,ES+DE组HR明显降低(P<0.01,P<0.05);与C组比较,ES+DE组T2时MAP明显下降,差异有统计学意义(P<0.01)。3组术后6、24及48 h疼痛评分差异均无统计学意义(P>0.05)。与C组及ES组相比,ES+DE组不良反应及神经精神症状发生率明显下降(P<0.01)。与C组及ES组比较,ES+DE组术后24 h及72 h焦虑症状明显减轻,差异有统计学意义(P<0.01,P<0.05)。结论 右美托咪定复合艾司氯胺酮可明显减轻乳腺癌患者术后焦虑及神经精神症状。

       

      Abstract: Objective To explore the effect of dexmedetomidine combined with esketamine on postoperative anxiety and neuropsychiatric symptoms in patients undergoing radical mastectomy for breast cancer. Methods A total of 130 patients who were scheduled for elective radical mastectomy under combined intravenous-inhalation anesthesia were randomly divided into three groups: control (group C), esketamine (group ES), and esketamine combined with dexmedetomidine (group ES+DE). In addition to baseline anesthetics which were the same in all groups, each group was continuously infused with the corresponding anesthetics, and pain management was performed with additional administration of the corresponding drugs in groups ES and ES+DE. Changes in heart rate (HR) and mean arterial pressure (MAP) were compared between groups during surgery. Postoperative adverse reactions and neuropsychiatric symptoms was recorded. Pain and anxiety scores were assessed. Results There were no statistical differences in general information among the three groups. Compared with groups C and ES, HR in group ES+DE significantly decreased at extubation (T2) (P<0.01 or P<0.05). Compared with group C, MAP in group ES+DE significantly decreased at T2 (P<0.01). There were no statistical differences in pain scores at postoperative 6, 24, and 48 h among the three groups (P>0.05). Compared with groups C and ES, group ES+DE showed significantly reduced incidences of adverse reactions and neuropsychiatric symptoms (P<0.01). Further results indicated that, compared with groups C and ES, group ES+DE presented significantly reduced anxiety symptoms at postoperative 24 and 72 h (P<0.01 or P<0.05). Conclusions The combination of dexmedetomidine and esketamine significantly alleviates postoperative anxiety and neuropsychiatric symptoms in breast cancer patients undergoing radical mastectomy.

       

    /

    返回文章
    返回